Aclaris therapeutics reports third quarter 2022 financial results and provides a corporate update

- completed enrollment in phase 2a trial of zunsemetinib in hidradenitis suppurativa; topline data expected in mid-first half of 2023
ACRS Ratings Summary
ACRS Quant Ranking